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Background: Tuberculosis (TB) still presents a leading cause of morbidity and mortality among people living with
HIV/AIDS (PLWHA), including those on antiretroviral therapy. In this study, we aimed to determine the long-term
incidence density rate (IDR) of TB and risk factors among PLWHA in relation to combination antiretroviral therapy
(cART)-status.
Methods: Data of PLWHA enrolled from 2001 through 2011 in the German ClinSurv HIV Cohort were investigated
using survival analysis and Cox regression.
Results: TB was diagnosed in 233/11,693 PLWHA either at enrollment (N = 62) or during follow-up (N = 171). The TB
IDR during follow-up was 0.37 cases per 100 person-years (PY) overall [95% CI, 0.32-0.43], and was higher among
patients who never started cART and among patients originating from Sub-Saharan Africa (1.23 and 1.20 per 100PY,
respectively). In two multivariable analyses, both patients (I) who never started cART and (II) those on cART shared
the same risk factors for TB, namely: originating from Sub-Saharan Africa compared to Germany (I, hazard ratio (HR);
[95% CI]) 4.05; [1.87-8.78] and II, HR 5.15 [2.76-9.60], CD4+ cell count <200 cells/μl (I, HR 8.22 [4.36-15.51] and II, HR
1.90 [1.14-3.15]) and viral load >5 log10 copies/ml (I, HR 2.51 [1.33-4.75] and II, HR 1.77 [1.11-2.82]). Gender, age or
HIV-transmission risk group were not independently associated with TB.
Conclusion: In the German ClinSurv HIV cohort, patients originating from Sub-Saharan Africa, with low CD4+ cell
count or high viral load at enrollment were at increased risk of TB even after cART initiation. As patients might be
latently infected with Mycobacterium tuberculosis complex, early screening for latent TB infection and implementing
isoniazid preventive therapy in line with available recommendations is crucial.
Keywords: Epidemiology, Incidence, HIV/AIDS, Tuberculosis, Coinfection, Antiretroviral therapy, Isoniazid preventive
therapy, Industrialized country, Germany, ImmigrationBackground
The co-infection of tuberculosis (TB) and Human
Immunodeficiency Virus (HIV) poses a major challenge
to public health for both developing and industrialized
countries [1]. According to WHO (2012) [2], an estimated
1.1 million new TB cases were reported among people
living with HIV/AIDS (PLWHA). TB still presents a lead-
ing cause of morbidity and mortality among PLWHA,* Correspondence: KaroB@rki.de; FiebigL@rki.de
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unless otherwise stated.including those on antiretroviral therapy (ART) [3]. The
greatest burden of TB/HIV co-morbidity was found in
Sub-Saharan Africa, where approximately 79% of global
TB/HIV cases occur [2]. Analogously, recent studies from
Europe showed that Sub-Saharan African immigrants
were at the highest risk of TB/HIV co-infection among
the general population [4-6].
Germany is a low incidence country for TB and a low
HIV-prevalence country. It has a population of 80.5 mil-
lion of whom about 8% are foreign nationals and 20%
are estimated to have a migration background, predom-
inantly from Turkey, Poland and Newly Independentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of TB has continuously fallen in the general population,
but the rate of decline has slowed in the last years
(9.3, 7.3, 5.5 and 5.3 cases per 100,000 population in
2002, 2005, 2008 and 2011, respectively) [8]. In the same
period, the number of newly diagnosed HIV cases has
substantially increased (1,719 cases in 2002 vs. 2,889 cases
in 2011) [9]. Individuals with foreign origin from high
burden countries are considered as risk groups for both
HIV and TB in Germany. Sub-Saharan Africa represents
the main foreign region of origin among PLWHA. While,
Turkey and the Newly Independent States of the former
Soviet Union are the main foreign countries of birth
among TB patients [8,9]. HIV prevalence in TB patients
was estimated to be 4.5% in 2009 [10]. But due to the separ-
ate reporting pathways of TB and HIV in the national
surveillance system [11], little is known on the TB/HIV
burden and risk factors of TB among PLWHA in Germany.
However, additional HIV surveillance instruments such as
the German ClinSurv HIV Cohort include information on
TB as an AIDS-defining disease.
The introduction of combination antiretroviral therapy
(cART) in the mid-1990s has markedly reduced HIV-
related morbidity and mortality [12,13]. The preventive
impact of ART on HIV-associated TB can be attributed to
suppression of viral replication, which permits both quan-
titative and functional reconstitution of the host’s immune
system [12]. Although cART is associated with substantial
declines in TB risk by 70%-90% among PLWHA [12], lim-
itations of cART in reducing TB risk have been observed
among some sub-populations such as elderly patients and
patients with low CD4+ cell count in high-income coun-
tries [14]. A study conducted in London to investigate the
effect of the initial cART on AIDS-related diseases over a
9-year period found no significant change in TB incidence
before and after the introduction of cART [15]. Antiretro-
viral treatment might be also complicated by the immune
reconstitution inflammatory syndrome (IRIS) in patients
who start anti-HIV medications during TB treatment man-
ifested by clinical deterioration in spite of increased CD4+
cell count and decreased plasma viral load [16].
Overall, little information is available on the risk pro-
files for TB among PLWHA living in Germany whether
cART has been initiated or not.
With this study, we aimed to describe the characteris-
tics of TB/HIV patients within the German ClinSurv
HIV Cohort; to estimate the TB incidence density rate;
and to identify factors associated with TB in PLWHA on
cART and those who never started cART.
Methods
Data source and study population
The study was based on the German ClinSurv HIV
Cohort, which is an ongoing open multicentre cohortfor the clinical surveillance of HIV disease. The ClinSurv
HIV cohort was established in 1999 as a collaborative co-
hort between specialized treatment centres for HIV/AIDS
and the Robert Koch Institute (the National Public Health
Institute of Germany). Irrespective of the disease stage,
all HIV-infected patients are eligible to attend one of
the treatment centres. After three consecutive days of
clinical observation, patients will automatically be en-
rolled in the ClinSurv HIV Cohort. The ClinSurv dataset
includes basic demographic data recorded anonymously at
the first contact. Additionally, clinical, laboratory and
medication history data are reported and updated at each
follow-up contact. More details on the German ClinSurv
HIV Cohort Study are provided by Baetzing-Feigenbaum
et al. [17].
For the current analysis, data of patients enrolled
in the cohort from January 2001 (introduction of the
co-formulation boosted protease inhibitors Lopinavir/
Ritonavir in Germany [18]) through December 2011
were extracted from the central ClinSurv HIV data-
base. Basic demographic characteristics including age,
gender and geographic origin are recorded as time-fixed
covariates at the time of enrollment. Clinical assessments
(diabetes mellitus, hepatitis B and C) are coded as binary
covariates. Laboratory measurements (CD4+ cell counts
and viral load) and medication information (TB regimens
and type of ART) are coded as time-varying covariates up-
dated in 3-month-periods when data is available.
Patients who received combination therapy involving two
nucleoside reverse-transcriptase inhibitors (NRTI) plus one
non-nucleoside reverse-transcriptase inhibitor (NNRTI)
or protease inhibitor were defined as patients on cART. The
remainder were classified as patients who never started
cART during follow-up, who may however receive a dif-
ferent form of ART.
TB/HIV case definition
TB cases were reported including date of diagnosis; pa-
tients diagnosed with TB prior to enrollment were ex-
cluded from the analysis. TB/HIV cases were defined as
any form of TB in PLWHA confirmed by positive cul-
ture of Mycobacterium tuberculosis complex. TB in
PLWHA is an AIDS defining disease; therefore all TB/
HIV patients were in the C category according to the
CDC classification system for the clinical categories of
HIV infection [19].
Statistical analysis
Continuous variables were described using medians with
interquartile ranges (IQR) and compared by the Mann–
Whitney U-test. Categorical variables were described using
numbers and percentages and compared by χ2 test.
For the survival analysis, the observation period was cal-
culated as the time from enrollment to either diagnosis of
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least one visit to center every 6 months) or the end of ob-
servation period (December 2011).
The TB incidence density rate (IDR) was defined as
the number of TB cases occurring per 100 patient-years
(PY) of observation. The TB IDR was further stratified
by gender, age group, region of origin, HIV-transmission
risk group, baseline CD4+ cell count, baseline viral load,
diabetes mellitus, hepatitis infections and cART-status.
P-value was obtained by χ2 test for difference in TB IDRs
among different groups. To compare TB IDRs after con-
trolling for region of origin and age, the Mantel-Haenszel
test was applied. Trend analyses of TB incidence were
conducted using the nonparametric test for trend across
ordered groups.
To compare survival probabilities between patients on
cART and those who never started cART, the observa-
tion period for patients on cART was modified to start
at the date when the patient first received cART and be-
fore TB diagnosis. Baseline CD4+ cell count and viral
load for patients on cART were set on the date of cART
initiation instead of enrollment. The endpoints of the
observation remained as defined in the survival ana-
lysis. We assumed that once started on cART, patients
remained on it.
The Kaplan-Meier survivor function was used to estimate
TB-free survival probabilities. TB-free survival was further
stratified by demographic factors, CD4+ cell count and
cART-status and was compared using log-rank tests. Two
multivariable Cox proportional hazards regression models,
one for patients on cARTand another for those never start-
ing cART were constructed to identify factors associated
with TB in relation to cART-status. Independent variables
(gender, age group, region of origin, HIV-transmission risk
group, baseline CD4+ cell count and viral load for patients
never started cART and CD4+ cell count and viral load
fixed at the time of cART initiation for the patients on
cART) with P < 0.02 in the log-rank test were included
in the Cox regression models. The proportionality as-
sumption of the final model was checked using the
likelihood-ratio test and the Schoenfeld and Scaled
Schoenfeld residuals. These applied tests indicated no
violation of the model’s proportionality. Furthermore,
the goodness of fit of the final model was evaluated
by the Cox-Snell residuals.
All tests were two sided with 95% confidence interval
(CI); the level of significance was P < 0.05. All analyses
were performed using STATA (version12, StataCorp, LP,
TX, USA) software.
Ethical statement
The ClinSurv HIV study protocol was approved by the
German Federal Commissioner for Data Protection and
Freedom of Information who stated that written informedconsent from the patients was not required due to the an-
onymous nature of the data.
Results
Characteristics of patients
From January 2001 through December 2011, a total of
11,865 patients were newly enrolled in the ClinSurv HIV
cohort. Of them, 172 patients were known to have TB
prior to enrolment and were therefore excluded from fur-
ther analyses. Of a total of 11,693 eligible HIV-positive
patients, 80% (N = 9,388) were men, 73% (N = 8,362)
originated from Germany and 12% (N = 1,403) from Sub-
Saharan Africa (Figure 1). About 80% of PLWHA received
cART during the follow-up. Patients aged > 38 years and
with low baseline CD4+ cell count and high viral load
were more likely to receive cART (multivariable logis-
tic regression; P < 0.05). No significant difference was
found in the distribution of cART between patients from
German and Sub-Saharan Africa (P = 0.79) (Table 1).
Of 11,693 patients, 233 were diagnosed with TB (N = 62)
at enrollment and (N = 171) during follow-up respect-
ively. The majority of TB/HIV co-infected patients were
male (167 cases (72%)). A large proportion of the female
patients originated from Sub-Saharan Africa (41 cases
(64% of 64 female patients)), while Germany was the main
origin among male patients (81 cases (51% of 159 male
patients)) (Table 2). At the time of enrollment, the median
CD4+ cell count was significantly lower among patients
who developed TB compared with those who did not
(197 cells/μl [IQR; 67–349], 322 cells/μl [IQR; 150–510]
respectively, P < 0.001). Only 130 (56%) patients of the
233 TB/HIV patients received cART at any point before
TB diagnosis. A total of 25 TB/HIV co-infected patients
had died during the investigation period (Table 2). Add-
itional clinical characteristics were presented in Table 2.
TB incidence density rate during follow-up
The median duration of follow-up was 40 months [IQR,
14–76]. The overall TB IDR was 0.37 cases per 100 person-
years [95% CI, 0.32-0.43] for a total observation of 45,698
person-years (Table 3).
The TB IDR was significantly higher among women
compared with men (0.49 vs. 0.34 per 100PY, respectively;
P = 0.04) and among patients originating from Sub-Saharan
Africa compared with those from Germany (1.20 vs. 0.21
per 100PY, respectively; P < 0.001). However, controlling
for region of origin revealed no significant difference in
TB IDRs between women and men (Mantel-Haenszel test;
P = 0.1).
The highest TB IDR was found among patients who
never started cART compared with those on cART (1.3 vs.
0.3 cases per 100PY respectively; P < 0.001). Furthermore,
significantly higher TB IDRs were found among patients
with the following clinical characteristics: baseline viral
Figure 1 Overview on the patients included in the study and their characteristics at enrollment in the ClinSurv HIV Cohort, Germany
2001–2011. TB, tuberculosis; MSM, men who have sex with men; IQR, interquartile range.
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cells/μl. A significantly lower TB IDR was found among
men who have sex with men (MSM) compared to other
HIV-transmission risk groups (P < 0.001).
The TB IDR was still significantly higher among pa-
tients with the aforementioned characteristics after con-
trolling for age groups (Mantel-Haenszel test).
Trend in TB incidence
The TB IDR was highest in the first year of follow-up at
1.07 per 100PY and decreased markedly in the second year
to 0.19 per 100PY (P < 0.001) (Table 3). A significant re-
duction in the IDR was indicated during the follow-up for
both patients on cART and those who never started cART
(P < 0.001 for trend) (Figure 2). TB IDRs among patients
on cART decreased further after the second year, while
TB IDRs among those who never started cART tended to
fluctuate and remained substantial (Figure 2).Kaplan-Meier survival probability estimates
The TB-free survival probability for the total cohort
over the 10-year follow-up was 97% [95% CI 96%-98%]
(Figure 3a). The 10-year TB-free survival proportion
was significantly higher among patients on cART com-
pared with those who never started cART (98% and 95%,
respectively; P < 0.001) (Figure 3b). Among patients on
cART, a significant lower TB-free survival proportion was
found in patients originating from Sub-Saharan Africa
compared with patients from Germany (93% and 99%,
respectively; P < 0.001) (Figure 3c) and in patients with
CD4+ cell count ≤200 cells/μl compared with patients
with CD4+ cell count >200 cells/μl (98% and 99%, re-
spectively; P < 0.001) (Figure 3d). The lowest TB-free
survival proportion was among patients who never
started cART, had a CD4+ cell count ≤200 cells/μl and
originating from Sub-Saharan Africa (60%; P < 0.001) (data
not shown).
Table 1 Demographic and clinical characteristic of people living with HIV/AIDS by cART status in the ClinSurv HIV
Cohort, Germany 2001–2011
Characteristic Non-cART cART* Total
N = 2,467 (21.1%) N = 9,226 (78.9%) N = 11,693 (100%)
TB patients 103 (4.2%) 130 (1.4%) 233 (2%)
Gender
Male 1.994 (80.8%) 7,394 (80.2%) 9,388 (80.3%)
Female 473 (19.2%) 1,831 (19.9%) 2,304 (19.7%)
Age at enrollment, years
Median [IQR] 35 [29–42] 39 [32–46] 38 [31–45]
≤38 1,468 (59.6%) 4,338 (47.1%) 5,806 (49.7%)
>38† 994 (40.4%) 4,873 (52.9%) 5,867 (50.3%)
Geographical origin
Germany 1,731 (72.1%) 6,631 (73.0%) 8,362 (72.8%)
Sub-Saharan Africa 255 (10.6%) 1,066 (11.7%) 1,321 (11.5%)
HIV-transmission risk group
MSM 1,339 (60.3%) 4,768 (57.8%) 6,107 (58.4%)
Other 881 (39.7%) 3,477 (42.8%) 4,358 (41.6%)
CD4+ cell count at enrollment in the cohort, cells/μl
Median [IQR] 492 [349–663] 273 [118–453] 320 [146–508]
>200 2,054 (89.1%) 5,467 (61.9%) 7,521 (67.6%)
≤200† 251 (10.9%) 3,362 (38.1%) 3,613 (32.5%)
Viral load at enrollment in the cohort, log10 copies/ml
Median [IQR] 4.2 [3.4 – 4.8] 4.5 [3.1 – 5.2] 4.4 [3.3 – 5.7]
<5 1,769 (72.9%) 5,845 (68.1%) 7,614 (70.5%)
≥5† 446 (20.1%) 2,737 (31.9%) 3,183 (29.5%)
Calendar year of enrollment
2001 147 (5.9%) 765 (8.2%) 912 (7.7%)
2002 166 (6.7%) 832 (9.0%) 998 (8.4%)
2003 178 (7.2%) 839 (10.1%) 1,017 (8.7%)
2004 205 (8.3%) 928 (10.1%) 1,133 (9.7%)
2005 213 (8.6%) 908 (9.8%) 1,121(9.5%)
2006 225 (9.1%) 842 (9.1%) 1,067 (9.1%)
2007 251(10.2%) 893 (10.6%) 1,144 (9.8%)
2008 217 (8.8%) 883 (9.5%) 1,100 (9.4%)
2009 249 (10.1%) 835 (9.1%) 1,084 (9.3%)
2010 278 (11.3%) 811 (8.8%) 1,089 (9.3%)
2011 338 (13.7%) 690 (7.5%) 1,028 (8.8%)
Length of follow-up (person-years)
Median [IQR] 1.2 [0.3-2.8] 3.1 [1.3-5.9] 2.5 [1.1-5.3]
cART, combination antiretroviral therapy; TB, tuberculosis; IQR; interquartile range; MSM, men who have sex with men; PWID, person who inject drugs; HPC, high
HIV-prevalence countries.
*cART initiated during follow-up at any time prior to TB diagnosis.
†Significantly associated with receiving cART (multivariable logistic regression model including all presented characteristics as independent variables; P < 0.05).
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Table 2 Demographic and clinical characteristic of people living with HIV/AIDS diagnosed with TB at enrollment and
during follow-up in the ClinSurv HIV Cohort, Germany 2001–2011
Characteristics Female Male Total
N = 66 (28.3%) N = 167 (71.7%) N = 233 (100%)
Median age at enrollment (N = 232/1 missing data) Median [IQR] 31 [26–45] 40 [32–47] 37 [30–45]
Median age at the time of TB diagnosis, years (N = 251/1 missing data) Median [IQR] 32 [28–39] 40 [32–48] 37 [31–45]
Region of origin (N = 223/10 missing data) N. (%)
Germany 8 (12.5) 81 (50.9) 89 (39.9)
Sub-Saharan Africa 41 (64.1) 41 (25.8) 82 (36.8)
Other countries 15 (23.4) 37 (23.3) 52 (23.3)
HIV-transmission risk group (N = 214/19 missing data) N. (%)
MSM — 67 (43.8) 67 (31.3)
PWID 3 (4.9) 17 (11.1) 20 (9.4)
HPC 54 (88.5) 43 (28.1) 97 (45.3)
Others† 4 (6.6) 26 (16.9) 30 (14.0)
Median CD4+ blood cell count at enrollment (N = 221/12 missing data) Median [IQR] 197 [67–349] 204 [67–375] 189 [66–348]
Median CD4+ blood cell count at the time of TB diagnosis
(N = 194/39 missing data)
Median [IQR] 211 [65–339] 198 [47–339] 216 [69–350]
Median viral load at enrollment (log10copies/ml) (N = 210/23 missing data) Median [IQR] 4.8 [3.6-5.4] 4.7 [3.4-5.5] 4.9 [3.6-5.3]
Median viral load at the time of TB diagnosis (N = 145/88 missing data) Median [IQR] 5.0 [4.3-5.6] 5.2 [4.5-5.7] 5.9 [3.9-5.5]
Hepatitis B* (N = 233) Median [IQR] 25 (37.9) 39 (23.4) 64 (27.5)
Hepatitis C* (N = 233) Median [IQR] 5 (7.6) 18 (10.8) 23 (9.9)
Diabetes mellitus* (N = 233) Median [IQR] 2 (3.0) 5 (3.0) 7 (3.0)
cART‡ (N = 233) Median [IQR] 31 (50.0) 99 (59.3) 130 (55.8)
Died (N = 233) N. (%) 4 (10.6) 18 (10.8) 25 (10.7)
TB, tuberculosis; MSM, men who have sex with men; PWID, person who inject drugs; HPC, high HIV-prevalence countries; cART, combination antiretroviral therapy;
IQR, interquartile range.
*At any time during follow-up.
†Others included heterosexual, blood transfusion and mother to child transmission.
‡cART initiated during follow-up at any time prior to TB diagnosis.
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In the multivariable analyses including gender, region of
origin, HIV-transmission groups, CD4+ cell count and
viral load as explanatory variables; risk factors of TB
in patients who never started cART were: originating
from Sub-Saharan Africa (Hazard ratio (HR) 4.05; 95%
CI 1.87-8.78; P < 0.001), CD4+ cell coun t ≤ 200 cells/μl
(HR 8.22; 95% CI 4.36-15.51; P < 0.001) and viral load ≥5
log10 copies/ml (HR 2.51; 95% CI 1.33-4.75; P = 0.005)
(Table 4).
Patients on cART shared the same risk factors of TB
with the patients who never started cART, namely: origin-
ating from Sub-Saharan Africa (HR 5.15; 95% CI 2.76-
9.60; P < 0.001), CD4+ cell count ≤ 200 cells/μl (HR, 1.90;
95% CI 1.14-3.15; P = 0.013) and viral load ≥ 5 log10 cop-
ies/ml (HR 1.77; 95% CI 1.11-2.82; P = 0.016). Addition-
ally, other geographic origins were significantly associated
with TB risk in patients on cART (Table 4).
Although MSM was negatively associated with the
diagnosis of TB in univariable analyses (data not shown),it was not associated with risk of TB in the multi-
variate analyses. Gender and age were also not inde-
pendently associated with TB risk in PLWHA in both
models.
Discussion
This study investigated the long-term TB incidence and
risk factors among PLWHA in Germany. A specific fea-
ture of the study is that it is not restricted to patients re-
ceiving cART, but determines TB IDR and TB risk
factors also for patients who never started cART. The
ClinSurv HIV Cohort used in this study is characterized
by a long duration of follow-up and broad enrollment
criteria of PLWHA irrespective of their age, disease
stage or ART-status. Therefore, this instrument allowed
us to calculate long-term TB incidence rate and to
determine associated risk factors with high precision
and to update existing estimates [20]. This enhances
the generalizability of the study results to other coun-
tries with low TB and HIV incidence.
Table 3 TB incidence density rate stratified by baseline demographic and clinical characteristics in the ClinSurv HIV
Cohort, Germany 2001–2011
Characteristics No. of patients Person-years No. with TB TB IDR [95% CI] P value*
Total patients 11,631 45,698 170 0.37 [0.32-0.43]
Gender 0.04
Female 2,283 9,153 45 0.49 [0.37-0.66]
Male 9,347 36,536 125 0.34 [0.29-0.41]
Median age, years 0.41 (NS)
≤38 5,773 23,250 91 0.39 [0.32-0.48]
>38 5,838 22,387 78 0.35 [0.28-0.43]
Region of origin <0.001
Germany 8,344 33,449 71 0.21 [0.17-0.27]
Sub-Sahara Africa 1,298 4,871 59 1.20 [0.94-1.56]
Other countries 1,789 6,710 34 0.52 [0.38-0.71]
HIV-transmission risk group category <0.001
MSM 6,093 24,189 53 0.22 [0.17-0.28]
HPC 1,528 5,910 69 1.17 [0.92-1.48]
PWID 943 3,534 14 0.42 [0.23-0.67]
Others† 1,846 7,768 22 0.28 [0.18-0.43]
CD4+ blood cell count (cells/μl) <0.001
>350 5,037 19,702 44 0.22 [0.17-0.30]
200–350 2,459 9,893 37 0.36 [0.26-0.50]
<200 3,580 14,111 82 0.58 [0.47-0.72]
Viral load (log10 copies/ml) <0.001
<5 7,583 30,137 92 0.31 [0.25-0.37]
≥5 3,162 12,490 65 0.52 [0.41-0.66]
Antiretroviral therapy <0.001
Never started cART 2,424 4,801 59 1.23 [0.95-1.59]
cART during follow-up 9,207 40,897 111 0.27 [0.23-0.33]
Follow-up <0.001
First year 2,421 10,174 109 1.07 [0.89-1.29]
Second year 1,615 8,248 16 0.19 [0.12-0.32]
TB, tuberculosis; IDR, incidence density rate (cases per 100 person-years); CI, confidence interval; NS, non-significant; MSM, men who have sex with men; HPC, high
HIV-prevalence countries; PWID, person who inject drugs; cART, combination antiretroviral therapy.
*Obtained by χ2 test for difference in TB IDR.
†Others included heterosexual, blood transfusion and mother to child transmission.
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Cohort, 233 were diagnosed with TB. Nearly 27% (N = 62)
of TB cases were diagnosed at enrollment represent-
ing prevalent TB at time of clinic entry rather than
true incident TB; a diagnosis of these TB episodes
may have promoted HIV testing. These TB cases could
potentially have been averted if individuals have been
offered early HIV testing and enrolled early in a treat-
ment center.
The TB IDR among HIV-positive patients in this study
was 0.37 per 100PY; this result is consistent with findings
from other studies conducted in high-income coun-
tries. A study from France showed that TB IDR was0.4 per 100PY [6] and a study from the United Kingdom
found that TB IDR was 0.3 per 100PY [4].
Previous studies attributed the great reduction of TB
incidence, in the short term, to cART initiation [21-23].
In our study, we demonstrate a significant decrease in
TB incidence density rate also among patients who
never started cART during the second year. Therefore,
the short-term impact of cART on TB incidence should
be interpreted with caution. A higher TB rate in the
first year could be due to late HIV diagnosis or closer
TB monitoring in HIV-infected patients. However, the
present data show that the TB incidence remained
low during 10 years among patients on cART. This
Figure 2 The trend of tuberculosis incidence density rate during follow-up, among (a) patients who never started cART (N = 59) and
(b) patients on cART (N = 111) in the ClinSurv HIV Cohort, Germany 2001–2011. A low number of patients who never started cART
remained under observation beyond 4 years of follow-up, where no TB cases reported in the 5th, 7th, 8th, 9th and 10th years of follow-up.
P < 0.001 for trend for TB incidence in patients who never started cART and patients on cART.
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study (the CASCADE cohorts) [24]. Nevertheless, among
patients on cART the TB rate did not further decrease in
the long term. This is consistent with the immunological
fact that cART has limitations in normalizing immune cell
phenotype and function and fails to reduce the TB inci-
dence to a level similar to that in an HIV-negative popula-
tion [12,25]. It is not clear why a significant reduction
in TB incidence rate among patients who never started
cART occurred in the second year. One explanation could
partly be a result of survival bias, as the majority of
deaths in the cohort (47%) occurred in the first year
of observation. The low number of patients who never
started cART as well as low TB frequency among them
beyond 4 years of follow-up prevented comparison of the
TB trend in relation to cART beyond this time point.
The data from our study confirm that originating from
Sub-Saharan Africa was independently associated with
increased TB risk. Similar findings were reported in an-
other study done in France, where the relative risk of TB
was 2.16 among PLWHA originating from Sub-Saharan
Africa compared with patients born in France [6]. These
findings can be explained in light of the high latent TB
infection (LTBI) prevalence and TB incidence in their
country of origin [2]. Furthermore, a wide range of socio-
economic, cultural and legal factors may also play a role
in increased vulnerability to TB among immigrants interm of high-risk behavior and barriers to health care ser-
vices [26], even though access to TB and HIV care is sup-
posed to be free in Germany. The presumably high LTBI
prevalence among PLWHA originating from Sub-Saharan
Africa might expose them to a particular risk of IRIS trig-
gered by host immune responses restored after the initi-
ation of cART [27,28].
Consistent with other findings from studies done in
developing and industrialized countries [6,21-24,29,30],
lower CD4+ cell count and higher viral load level at en-
rollment were independently associated with higher risk
for TB.
Both patients on cART and those who never started
cART share the same risk factors for TB. This evidence
highlights the need for early screening of LTBI and offer-
ing isoniazid preventive therapy (IPT); particularly to pa-
tients originating from Sub-Sahara Africa and those with
poor immune status. In the ClinSurv HIV Cohort only
0.1% of 11,693 PLWHA without TB were reported to re-
ceive isoniazid (data not shown). This might be partly
related to incomplete recording of this information but
could also indicate low level of IPT implementation
in Germany. A similar finding was shown by a French
study, which showed that IPT was rarely implemented
in France in PLWHA [6].
IPT can dramatically reduce the risk of TB among
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Figure 3 Kaplan-Meier plots of tuberculosis (TB)-free survival proportion in the ClinSurv HIV Cohort, Germany 2001–2011. (a) among all
patients; (b) among all patients stratified by combination antiretroviral therapy (cART)-status; (c) among all patients stratified by region of region;
(d) among all patients stratified by CD4+ cell count; (e) among patients who never started cART stratified by region of origin; (f) among patients
who never started cART stratified by CD4+ cell count; (g) among patients on cART stratified by region of origin; (h) among patients on cART
stratified by CD4+ cell count. Observation period for patients who never started cART began at enrollment, while for patients on cART began at
the time of cART initiation.
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line strongly recommends IPT to HIV patients without
active TB irrespective of immune status and whether or
not a person is on ART [32]. The British HIV Association
Guideline identified HIV patients with increased risk for
TB as being from sub-Saharan Africa, with CD4+ cell
count <350 cells/μl, or duration of cART <6 months and
recommended that these patient groups should be offered
screening for LTBI and given TB chemoprophylaxis if the
test result is positive [34]. Our findings support these
recommendations and we therefore recommend a similar
approach to be implemented in Germany.
This study has several limitations. A geographical bias
related to distribution of collaborating treatment centres
of the ClinSurv HIV Cohort can be noticed; cities
with a relatively high notification rate of TB and HIV in
Germany like Stuttgart, Frankfurt and Nuremberg [9]
are left without local collaborating centres [17]. Thecollaborating centres are mainly specialized to treat pa-
tients with advanced disease stage, thus patients with
HIV C-classification, including those with TB, might be
overrepresented in the cohort. Bätzing-Feigenbaum et al.
[17] also found that patients originating from high HIV-
prevalence countries were slightly underrepresented in
the ClinSurv HIV Cohort compared to national HIV sur-
veillance data, which could be an expression of greater
difficulty in accessing specialized treatment centres.
This implies that this study underestimates the actual
TB/HIV burden in Germany. It is unknown whether TB
diagnosis was routinely implemented to all PLWHA
(active case finding) or whether it was just a part of on-
going health care (passive case finding); therefore some
TB cases may not have been detected.
Discussion is also necessary on whether the TB case
definition in the ClinSurv HIV Cohort (culture-positive)
is strictly implemented, which might underestimate the
Table 4 Cox proportional hazards analysis of factors associated with TB among people living with HIV/AIDS in the
ClinSurv HIV Cohort, Germany 2001–2011
Predictor variable Patients never started cART* Patients on cART†
HR [95% CI] P value HR [95% CI] P value
Gender
Female 1 1
Male 0.73 [0.36-1.47] 0.38 (NS) 1.49 [0.84- 2.62] 0.17 (NS)
Median age, years
≤38 1 1
>38 0.86 [0.47-1.58] 0.62 (NS) 1.42 0.89 2.27 0.14 (NS)
Region of origin
Germany 1 1
Sub-Saharan Africa 4.05 [1.87-8.78] <0.001 5.15 [2.76-9.60] <0.001
Other countries 1.75 [0.81-38.1] 0.16 2.22 [1.18-4.20] 0.014
HIV-transmission risk group
Others† 1 1
MSM 0.68 [0.31-1.51] 0.34 0.60 [0.32-1.10] 0.10 (NS)
CD4+ cell count (cells/μl)
≥200 1 1
<200 8.22 [4.36-15.51] <0.001 1.90 [1.14-3.15] 0.013
Viral load (log10 copies/ml)
< 5 1 1
≥ 5 2.51 [1.33-4.75] 0.005 1.77 [1.11-2.82] 0.016
HR, hazard ratio; CI, confidence interval; NS, non-significant; MSM, men who have sex with men.
*50 TB cases among 1,919 subjects. †78 TB cases among 6,357 subjects.
†Others included heterosexual, blood transfusion and mother to child transmission.
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http://www.biomedcentral.com/1471-2334/14/148TB burden. Some TB cases could have also been clinic-
ally diagnosed and recorded in the ClinSurv HIV Cohort
(yet was not provable case-by-case), because these TB
cases are also mandatorily notified within the German
TB surveillance. Due to lack of data, we were unable to
include some factors known to be associated with TB
in our analysis such as smoking [35], homelessness [36],
alcohol abuse [37], incarceration [38] and other socio-
economic factors.
Conclusion
In conclusion, the German ClinSurv HIV Cohort repre-
sents a highly valuable data source to study the occur-
rence of TB/HIV in Germany. A reasonable amendment
to the instrument would be the systematic collection of
data on LTBI and TB diagnostics done and the comple-
tion of data on IPT.
Particularly, patients originating from Sub-Saharan
African countries with high incidence of TB, and those
with low CD4+ cell count and high viral load were at in-
creased risk of TB even after cART initiation. This sug-
gests that actions beyond timely cART initiation should
be considered; including early screening for LTBI and of-
fering IPT in line with available recommendations.Abbreviations
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